Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reneo Pharmaceuticals Inc.

Latest From Reneo Pharmaceuticals Inc.

Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program

AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.

Deals Financing

Reneo Reveals $50m Series A, Mitochondrial Disease Development Plans

The start-up run by ex-Lumena leadership is testing REN001 for rare genetic mitochondrial diseases with two Phase Ib trials under way and plans to start a third later this year.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Reneo Pharmaceuticals Inc.
  • Senior Management
  • Niall O’Donnell, PhD, Pres. & CEO
    Alejandro Dorenbaum, MD, CMO
  • Contact Info
  • Reneo Pharmaceuticals Inc.
    Phone: (858) 283-0280
    12230 El Camino Real, Ste. 230
    San Diego, CA 92130
    USA
UsernamePublicRestriction

Register